You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Supporting Healthy Aging with a Phytochemical Combination that Acts at Multiple Control Points in the Nrf Activation Pathway
SBC: Pathways Bioscience, LLC Topic: NIAThe average lifespan and the number of older individuals is increasing in the US but because age is a primary risk factor for most chronic disease there is an accompanying increase in the burden of chronic disease in the US Diet and lifestyle choices including dietary supplementation may be useful approaches to slowing the aging process and increasing healthspan and also may be the best stra ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Enhancing cytarabine efficacy in leukemia through CDK inhibition
SBC: SENEX BIOTECHNOLOGY, INC. Topic: 102Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
"Modulation of Immune Checkpoints by Self Deliverable RNAi for Adoptive Cell Transfer"
SBC: ADVANCED RNA TECHNOLOGIES, LLC Topic: 102Two of the most promising approaches to cancer immunotherapy are immune checkpoint blockade by monoclonal antibodies and the adoptive transfer of immune cells The recent successes in treating melanoma with anti PD and anti CTLA antibodies as well as the extremely successful application of T cells engineered to express the CAR receptor targeting CD to treat B cell lymphomas initiated a waterfal ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
High sensitive and specific Point of use lateral flow strip for on site test of cannabis intoxication
SBC: VITAN-BIOTECH LLC Topic: NIDAProject Summary Marijuana e g cannabis is the most frequently detected drug of abuse Cannabis abuse has a substantial impact on public safety as driving under the influence of cannabis will impair driving skill and the marijuana use in the workplace will increase the risk of adverse events and the loss of productivity With the recent wave of legalization of marijuana use in numerous states ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel injectable resiquimod formulation for treatment of metastatic cancers
SBC: Curebiotech, Inc. Topic: NCIPROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens
SBC: Theragnostic Technologies Inc. Topic: NIAIDAbstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Treatment of NTM Respiratory Infections with Inhaled Drug Delivery
SBC: AEROPHASE, INC. Topic: NIAIDProject Summary AbstractDescriptionSignificanceNon tuberculous mycobacteriaNTMrespiratory infections is increasing across the globeIn the USin those overyears oldannual prevalence of pulmonary NTM disease increased significantly fromtocasesbetweenwith Hawaii having the highest prevalence atcasesPulmonary NTM istimes more common in womenThese numbers are likely underestimated because of a lack of m ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Nitric Oxide Polymer Platform for the Prevention and Treatment of Infected Wounds
SBC: IFYBER LLC Topic: NIAIDThis proposed SBIR research effort will lay the foundation for commercializing a new class of biomaterial for the prevention and treatment of infected skin wounds thereby enhancing patient health through improved patient outcome and reduced patient morbidity Specifically we will focus on evaluating and developing a biomaterial comprised of a nitric oxide NO releasing based on a commonly used ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Fluorescent reporters for real time single cell Pol III transcription measurement
SBC: LUCERNA INC Topic: 400SUMMARY RNA polymerase III Pol III is increasingly recognized as an important drug target and a rapidly developing area of academic research Pol III is responsible for generating RNAs that are critical for cell growth such as tRNAs certain rRNAs and various noncoding RNAs involved in processes such as mRNA splicing These RNAs are required for cell growth proliferation and differentiation ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Topical Nrf Activator for Oral Mucositis
SBC: Pathways Bioscience, LLC Topic: NIDCRWe propose to develop a topical formulation for preventing or treating oral mucositis Oral mucositis is a common and harmful side effect of radiation therapy and chemotherapy in cancer patients that affects nearly patients in the US annually and can be dose limiting impairing the clinical ability to continue the otherwise needed therapy and that also greatly impacts the patientandapos s ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health